In this IJGC podcast, Dr. Pedro Ramirez discusses Checkpoint Inhibitor Rechallenge in Endometrial Cancer with Brian Slomovitz.

Dr. Slomovitz is a Gynecologic Oncologist at Mount Sinai Medical Center in Miami Beach, Florida, and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.

In this IJGC podcast, Dr. Pedro Ramirez discusses PEACOCC Trial: Pembrolizumab in Clear Cell Cancer with Rebecca Kristeleit.

Rebecca Kristeleit is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and an Adjunct Associate Professor in the Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences at KCL, London. She is Research Lead for gynaecological cancer, R&D Lead for Oncology and Clinical Lead for Oncology and Haematology Clinical Trials at Guy’s and St Thomas’ NHS Foundation Trust. She works as a Principle Investigator within the KCL Cancer Early Phase Trials Unit, Theme Lead within King’s Health Partners ECMC and is Academic Lead for the King’s Health Partners Gynaecological Cancer Biobank.  Rebecca has extensive experience in experimental therapeutics and associated translational research, particularly molecular selection for therapeutics, as well as Phase II and III clinical trials. She works closely with several academic collaborators at KCL, nationally and internationally. She is currently leading two trial programmes of drugs discovered at KCL, a novel immunotherapy and a solid tumour CAR-T. She mentors and supervises KCL undergraduate and postgraduate students. Rebecca’s primary motivation is to improve treatment options available for patients with gynaecological cancer and she has been instrumental in the development and delivery of new licensed drugs in gynaecological cancer, for example rucaparib, dostarlimab, through clinical trial research leadership. She led the UK academic PEACOCC trial investigating pembrolizumab in clear cell gynaecological cancer and is global Co-Investigator for DOVE, a follow-on international randomised Phase II trial in the same rare indication. She leads many trials nationally and internationally, several in partnership with GTG-UK. Rebecca has published extensively, speaks regularly at International Conferences and has held several national and international research leadership positions including Chair BGCS Scientific Committee, BGCS guidelines committee, BGCS medical oncology representative, Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, CRUK New Agents Committee, ESMO Faculty, Chair ASCO Gynaecological Cancer Scientific Committee, ASCO educational committee.

In this IJGC podcast, Dr. Pedro Ramirez discusses ADCs and Oral Mucositis: Strategies for Gynecologic Oncologists with Michelle D. Lightfoot.

Michelle D. Lightfoot, MD, joined NYU Langone in August 2021 after completing fellowship training in gynecologic oncology at The Ohio State University. She received her medical degree from Harvard Medical School and a master’s in public health from Columbia University’s Mailman School of Public Health, before completing residency training at Beth Israel Deaconess Medical Center/Harvard Medical School.

At NYU Langone’s Perlmutter Cancer Center and Bellevue Hospital, Dr. Lightfoot provides clinical care and is committed to training future generations of physicians and gynecologic oncologists. As a physician–researcher, she is dedicated to improving care for women with gynecologic malignancies through research, quality improvement initiatives, and public health measures. She also serves on the Society of Gynecologic Oncology’s policy, quality, and outcomes subcommittee.

In collaboration with researchers at NYU Langone Health’s Institute for Excellence in Health Equity, Dr. Lightfoot’s research focuses on identifying and eliminating disparities in cancer care delivery and outcomes among women with gynecologic cancers

In this episode of the IJGC conversations 2025 October Editor's Choice, Editorial Fellow Tommaso Meschini and Carlotta Sabini discusses the contents of the 2025 October issue of IJGC. 

In this IJGC podcast, Dr. Pedro Ramirez discusses ROSELLA Trial: Relacorilant in Platinum-resistant Ovarian Cancer with Alexander B. Olawaiye.

Dr. Olawaiye a Professor and  Vice Chair for DI at the Department of Obstetrics, Gynecology and Reproductive Sciences. He is director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center, and has overseen multiple clinical research projects. He is also the Gynecologic Oncology Group Foundation principal investigator for the University of Pittsburgh Cancer Institute and in this role has collaborated with multiple clinical scientists across the country to conduct phases I, II and III studies. As well as a co-principal investigator on the University of Pittsburgh ovarian cancer SPORE program. Dr. Olawaiye also studies chemotherapeutic agents and their complications, along with mentoring many younger clinicians at the beginning of their academic careers. His recent work published in LANCET, the phase 3 ROSELLA trial, tested the combination of Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer. 

In this IJGC podcast, Dr. Pedro Ramirez discusses Carcinosarcoma with no myoinvasion with Giuseppe Cucinella and Mario M. Leitao, Jr.

In this episode of the IJGC conversations 2025 September Editor's Choice, Editorial Fellow Filippo Capomacchia and Natalia Teixeira discusses the contents of the 2025 September issue of IJGC. 

In this IJGC podcast, Dr. Pedro Ramirez discusses SENTIX Trial with David Cibula.

Dr. David Cibula graduated from the First Faculty of Medicine at Charles University in Prague in 1992. Since 2003, he has served as the Chair of the Gynecological Oncology Center at the University Hospital in Prague, and in 2022, he became the head of the Department of Gynecology, Obstetrics, and Neonatology.

He is a former President of the European Society of Gynecologic Oncology and previously led the International Group for Guidelines and Quality Indicators in Cervical Cancer. He is the founder and chair of the Central and Eastern European Group for Clinical Trials in Gynecologic Oncology, a member of ENGOT. Dr. Cibula has also established two charitable organizations supporting patients with gynecologic cancers and promoting research in the field.

He is the author or co-author of hundreds of scientific publications. His recent article in Nature Cancer presents the final results of the SENTIX study on sentinel lymph node biopsy in early-stage cervical cancer.

In this IJGC podcast, Dr. Pedro Ramirez discusses RAMP 201 Results: Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer with Susana N Banerjee and Rachel N. Grisham.

Prof Susana Banerjee MBBS MA PhD FRCP is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, London. She is also Professor in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers. Prof Banerjee is President of the Royal Society of Medicine Oncology Section.

Prof Banerjee graduated with a 1st class in Physiology from St John’s College, University of Cambridge. She was president of the Cambridge Medical Society in 1996-1997. She completed her medical training in 2000 at The Royal Free/University College London Medical School where she was a University of London Gold Medal finalist. Dr Banerjee gained a PhD from The Institute of Cancer Research in 2009, University of London and was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Other prizes include the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize and the Pfizer British Oncology Association Young Investigator Award (highly commended). She received The Fellow of ESMO (FESMO) Award in 2023.

Prof Banerjee has served in international specialist groups including the European

Prof Banerjee is an author of over 200 peer-reviewed publications including in the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers. Prof Banerjee has Global and UK Chief Investigator roles of over 30 national and international clinical trials. She led the ENGOTov60/GOG3052/RAMP201 trial globally which resulted in FDA accelerated approval for avutometinib and defactanib - the first approved therapy specifically for low grade serous ovarian cancer.

Dr. Rachel N. Grisham is a medical oncologist and internationally recognized expert in gynecologic cancers, with a particular focus on low-grade serous ovarian carcinoma (LGSOC) and rare ovarian malignancies. She has played a leading role in advancing systemic therapy for ovarian cancer through clinical trials, translational research, and national guideline development.

Dr. Grisham has been at the forefront of evaluating novel targeted therapies for LGSOC, including MEK inhibitors, avutometinib, and defactinib, as well as hormone-directed strategies and combinations with novel agents. She has served as principal or co-investigator on multiple pivotal trials, including ENGOT-OV60/GOG-3052/RAMP 201 and RAMP 301, which are shaping the future treatment landscape for recurrent LGSOC. Her work extends to biomarker-driven approaches, exploring MAPK pathway alterations, homologous recombination deficiency, and folate receptor alpha expression, with the goal of developing precision oncology strategies in ovarian cancer.

In addition to clinical trials, Dr. Grisham has published extensively on the molecular landscape and clinicopathologic features of ovarian tumors, treatment paradigms for granulosa cell tumors and clear cell carcinoma, and the management of rare gynecologic neoplasms such as mesonephric-like adenocarcinomas. She is a co-author of the NCCN Guidelines for Ovarian, Fallopian Tube, and Primary Peritoneal Cancers, reflecting her leadership in shaping standards of care.

Her scholarly contributions include over a decade of influential publications in Journal of Clinical Oncology, Clinical Cancer Research, Gynecologic Oncology, International Journal of Gynecological Cancer, and Cancer. She has also authored consensus statements and state-of-the-science reviews that provide critical guidance for clinicians worldwide.

Through her clinical research, teaching, and collaborative international work, Dr. Grisham has made significant contributions to improving outcomes for women with gynecologic cancers, particularly those with low-grade serous ovarian cancer, a historically under-researched disease.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Tyler Hillman and Allison Lynn Brodsky to discuss Surgical Approach in Recurrent Granulosa Cell Tumor.

Tyler Hillman, MD, PhD, is a board-certified gynecologic oncologist at UC San Diego Health, where he specializes in medical and surgical management of gynecologic cancers, with expertise in minimally invasive surgery, symptom management, and novel therapies. An associate professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, he teaches medical students, residents, and fellows at UC San Diego School of Medicine.

Allison Lynn Brodsky, MD, MS, is a fellow in gynecologic oncology at The University of Texas MD Anderson Cancer Center.  She completed her OBGYN residency at the University of California San Diego. Her research interests include rare gynecologic tumors, clinical trial development, and quality improvement.